Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21316585 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Gao B, et al. (2011) Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell 20, 163-76 21316585
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S5-p - VANGL2 (mouse) ▲
Orthologous residues
VANGL2 (human): S5‑p, VANGL2 (mouse): S5‑p, VANGL2 (rat): S5‑p
Characterization
 Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1-D (mouse) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT5A (human) increase
D4476 WNT5A (human) inhibit treatment-induced increase
ROR2 (mouse) increase
D4476 ROR2 (mouse) inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activation, protein stabilization

S82-p - VANGL2 (mouse) ▲
Orthologous residues
VANGL2 (human): S82‑p, VANGL2 (mouse): S82‑p, VANGL2 (rat): S82‑p
Characterization
 Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1-D (mouse) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT5A (human) increase
D4476 WNT5A (human) inhibit treatment-induced increase
ROR2 (mouse) increase
D4476 ROR2 (mouse) inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activation, protein stabilization

S84-p - VANGL2 (mouse) ▲
Orthologous residues
VANGL2 (human): S84‑p, VANGL2 (mouse): S84‑p, VANGL2 (rat): S84‑p
Characterization
 Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  CHO (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  hamster
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1-D (mouse) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WNT5A (human) increase
D4476 WNT5A (human) inhibit treatment-induced increase
ROR2 (mouse) increase
D4476 ROR2 (mouse) inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activation, protein stabilization


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.